Rationalizing the R&D Structure and Building a Lean Management Foundation
First written in FY2020. 6 of 14 entries say "Restated". Latest entry: 2026-05-26.
Techno Medica moved to the "Worse" side of this theme in 2024.
1 other company's latest entry also says "Reframed".
- 2026-05-26ReframedFinancial results presentation
「Selling, general and administrative expenses are expected to remain in the ¥3.7 billion range throughout the three years of the medium-term plan, incorporating higher personnel expenses from wage increases and research and development expenses based on the R&D plan.」
The company continues to present an investment-oriented operating platform that incorporates R&D expenses and higher personnel expenses from wage increases into the medium-term plan. - FY2025ReframedAnnual report
「Selling, general and administrative expenses increased to ¥3,627.973 million, up 9.5% year on year, owing to proactive R&D investment in blood collection tube preparation equipment and systems and higher personnel expenses associated with wage increases,」
The focus has shifted from reducing various expenses and streamlining operations to an investment-oriented operating base, including proactive R&D investment in blood collection tube preparation equipment and systems and wage increases. R&D expenses were ¥690.523 million. - FY2024ReframedAnnual report
「During the fiscal year, the Company recorded R&D expenses of ¥404.027 million for blood collection tube preparation equipment and related systems and ¥112.223 million for specimen testing equipment, for a total of ¥516.250 million.」
The Company recorded total R&D expenses of ¥516.250 million and continues to emphasize proactive R&D investment and a transformation of its business structure based on the 2023 Medium-Term Management Plan, rather than focusing primarily on reducing various expenses and streamlining operations. - FY2024-Q3ReframedAnnual report
「Selling, general and administrative expenses increased to ¥2,300.961 million, up 5.7% year on year, owing to higher personnel expenses from wage increases as part of investment in human capital, higher education and training expenses, increased costs for developing the foundation of the R&D structure based on the investment plan, and higher costs associated with the systemization of operations,」
The focus of the explanation regarding the R&D structure expanded from reducing various expenses and streamlining operations to developing its foundation based on the investment plan and systemizing operations. - FY2024-Q2RestatedAnnual report
「R&D expenses for the cumulative second quarter period were ¥189.310 million. There were also no material changes in the status of the Company's R&D activities during the cumulative second quarter period.」
The Company recorded R&D expenses of ¥189.310 million but stated that there were no material changes in the status of its R&D activities. No new measures or milestones were presented regarding the streamlining of the R&D structure or the creation of a lean operating base. - FY2023-Q3RestatedAnnual report
「Total R&D expenses for the cumulative third quarter were ¥237.778 million. There were also no significant changes in the status of the company's R&D activities during the cumulative third quarter.」
The Company states that there have been no material changes in the status of R&D activities and presents no new measures or milestones related to streamlining the R&D structure or building a lean operating base. - FY2023-Q2RestatedAnnual report
「R&D expenses for the cumulative second quarter were ¥160.608 million. There were also no significant changes in the status of the company's R&D activities during the cumulative second quarter.」
The Company states that there have been no material changes in the status of R&D activities and presents no new measures or milestones related to streamlining the R&D structure or building a lean operating base. - FY2023-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter were ¥89.370 million. There were also no significant changes in the status of the company's R&D activities during the cumulative first quarter.」
The Company states that there have been no material changes in R&D activities and presents no new measures or milestones related to streamlining the R&D structure or building a lean operating base. - FY2022-Q2RestatedAnnual report
「R&D expenses for the cumulative second quarter were ¥187.104 million. There were also no significant changes in the status of the company's R&D activities during the cumulative second quarter.」
The Company stated that there were no material changes in R&D activities, and presented no new measures or milestones related to streamlining the R&D structure or building a lean operating base. R&D expenses were ¥187.104 million. - FY2022-Q1RestatedAnnual report
「Total R&D expenses for the cumulative first quarter were ¥77.347 million. There were also no significant changes in the status of the company's R&D activities during the cumulative first quarter.」
The Company stated that there were no material changes in R&D activities, and presented no new measures or milestones related to streamlining the R&D structure or building a lean operating base. R&D expenses were ¥77.347 million. - FY2021AdvancedAnnual report
「Selling, general and administrative expenses declined to ¥2,846.648 million, down 12.2% year on year, resulting in operating profit of ¥1,607.791 million, up 27.8% year on year. The main factor behind the decrease in selling, general and administrative expenses was the Company's efforts to reduce various expenses, including advertising and promotion expenses and travel expenses, as the impact of COVID-19 continued for an extended period.」
Efforts to reduce various expenses lowered selling, general and administrative expenses by 12.2% year on year and increased operating profit by 27.8%. R&D expenses were ¥433.255 million. - FY2021-Q3AdvancedAnnual report
「Selling, general and administrative expenses declined to ¥2,068.825 million, down 9.4% year on year, partly owing to efforts to reduce various expenses during the COVID-19 pandemic,」
The Company reduced various expenses during the COVID-19 pandemic, lowering selling, general and administrative expenses by 9.4% year on year. Specific measures toward building a lean operating base were presented. - FY2021-Q2AdvancedAnnual report
「In terms of profitability, gross profit declined to ¥1,769.037 million, down 16.7% year on year, in line with the decrease in net sales. Selling, general and administrative expenses declined to ¥1,364.367 million, down 10.0% year on year, owing to efforts to reduce various expenses during the COVID-19 pandemic and the curtailment of sales and R&D activities,」
The Company reduced various expenses during the COVID-19 pandemic and curtailed sales and R&D activities, resulting in a 10.0% year-on-year decrease in selling, general and administrative expenses. Specific measures toward a stable, lean operating base were presented. - FY2020First statedAnnual report
「While carrying out necessary investments decisively, the Company is also expected to focus on streamlining its R&D structure and building a more stable, lean operating base.」
The Company has for the first time explicitly presented measures to streamline its R&D structure and build a stable, lean operating base while continuing necessary R&D investment.